Maternal infection and immune involvement in autism by Patterson, Paul H.
MATERNAL INFECTION AND IMMUNE INVOLVEMENT IN
AUTISM
Paul H. Patterson
Biology Division, California Institute of Technology Pasadena, CA 91125 USA
Abstract
Recent studies have highlighted a connection between infection during pregnancy and increased
risk for autism in the offspring. Parallel studies of cerebral spinal fluid, blood, and postmortem
brains reveal an ongoing, hyper-responsive inflammatory-like state in many young as well as adult
autism subjects. There are also indications of gastrointestinal problems in at least a subset of
autistic children. Work with animal models of the maternal infection risk factor indicate that
aspects of brain and peripheral immune dysregulation can be begin during fetal development and
be maintained through adulthood. The offspring of infected, or immune-activated dams also
display cardinal behavioral features of autism, as well as neuropathology consistent with that seen
in human autism. These rodent models are proving useful for the study of pathogenesis and gene-
environment interaction, as well as for the exploration of potential therapeutic strategies.
Maternal infection and autism
There is little public awareness that infection during pregnancy significantly increases the
probability of the offspring becoming schizophrenic. In fact, it has been estimated that if
viral (influenza, Herpes simplex virus, rubella), bacterial (urinary tract) and parasitic
(toxoplasma) infections could be prevented in pregnant women, >30% of schizophrenia
cases could be eliminated (1). The public health implications are enormous, but not widely
recognized (2). Similarly, there is little public or scientific awareness that maternal infection
also increases the risk for development of autism in the offspring. An extraordinary recent
study of over 10,000 autism cases in the Danish Medical Register found a strong association
with maternal viral infection in the first trimester and a less robust, but significant
association with maternal bacterial infection in the second trimester (3). These new results
greatly extend prior work on the connection between maternal infection and autism (4).
Supporting the epidemiology, recent results with rodent models of the maternal infection
risk factor reveal that the offspring display features of autism, as well as immune-related
disruptions in the brain and periphery. Moreover, new work on human autism spectrum
disorders (ASD) reinforces this immune connection.
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Immune-related abnormalities in autism
A variety of organ systems exhibit inflammatory-like changes in autism. The evidence
comes from quantifying immune-related proteins and RNAs, as well as
immunohistochemistry. Findings from epidemiology are also relevant.
Brain and CSF
A groundbreaking paper by Carlos Pardo and colleagues (5) revealed an inflammatory-like
state in post-mortem autism brains as indicated by elevated cytokines and activated
microglia and astrocytes. Importantly, these changes were found in subjects ranging in age
from 5 to 44 years old, indicating that this immune-activated state is established early and
appears to be permanent. Moreover, cytokine elevation was also found in the cerebral spinal
fluid (CSF) of living autistic children ages 3 to 10 years old. Recent results from studies of
some of the same postmortem brains and new autism brain samples, as well as CSF, have
supported these conclusions (6, 7). Consistent with these findings are results from a variety
of microarray studies that show dysregulation of immune-related genes (e.g. cytokines and
chemokines) in autistic brains (8). It is also clear that there is considerable heterogeneity
among the autism samples, as might be expected from the extreme disparities in behavioral
symptoms among ASD subjects.
Peripheral immune system and GI tract
Possibly related to the inflammatory-like state in the central nervous system are
abnormalities in the peripheral immune system (9). Although there have been many papers
on this topic over the years, recent reports from Judy Van de Water and Paul Ashwood have
utilized blood samples from a well characterized, large cohort of ASD children. These
authors report that, compared to controls and non-ASD children with developmental
disabilities, several cytokines and chemokines, including interleukin-1β (IL-1β), IL-6, IL-8
and IL-12p40, are elevated in the ASD plasma of very young children (ages 2–5 years old),
and that these increases are associated with more impaired communication and aberrant
behaviors (8, 10, 11). In addition, peripheral blood mononuclear cells display altered
cytokine responses to stimulation in vitro (12, 13).
Although an early report from Wakefield and colleagues muddied the waters considerably,
there have been several subsequent papers providing evidence of inflammation in the
gastrointestinal (GI) tract of at least a subset of ASD children (14, 15). These findings
include immune cell infiltrates present in the colon, ileum and duodenum, as well as
increased T cell activation in the intestinal mucosa. These inflammatory changes are
associated with autoimmune responses that could contribute to the observations of decreased
mucosal integrity, or “leaky gut” (16). Disruption of the mucosal barrier can also occur in
the apparent absence of inflammation, however, as in irritable bowel syndrome. Thus, leaky
gut symptoms do not necessarily connote inflammation. This issue needs to be clarified in
ASD, as does the question of the frequency of GI symptoms in ASD compared to controls.
These are difficult questions to answer because of the problems in obtaining GI samples
from ASD and control children without overt GI symptoms. Perhaps related to GI symptoms
is the finding of an abnormal gut microbiota composition in ASD (17). It is thus of particular
interest that a small study of antibiotic treatment aimed at the gut found temporary
improvement in some behavioral symptoms (9). This is potentially important, as it
represents a possibly safe intervention and thus could be followed up with a large, blinded
study. In addition, dietary modification is reported to provide behavioral improvements for
some ASD children (14). There is considerable interest among parents of autistic children
regarding the possibility of adverse reactions to certain dietary components. This could then
lead to GI problems such as a leaky gut, which may or may not have an inflammatory basis.
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The possibility of a connection between peripheral immune abnormalities and altered
behavior in ASD is fascinating, but unsubstantiated, at this point. On the one hand, it could
be that genetic susceptibility or an environmental insult biases the subject toward both brain
and immune dysregulation simultaneously and that these symptoms occur independently.
For example, several ASD candidate genes are known to regulate both brain and immune
system development and/or function (9). On the other hand, it is possible that immune
irregularities, such as in peripheral immune cells or the GI tract, interact with an abnormal
brain to exacerbate behavioral symptoms. For instance, it is well known from animal and
human studies that elevated peripheral cytokines can cause striking changes in behavior (4).
Autoimmune connections
Further support for immune system dysregulation comes from epidemiologic studies of
ASD. The largest of these found that some autoimmune diseases (rheumatoid arthritis, celiac
disease and type 1 diabetes) are more common in mothers of ASD children than in mothers
of typically developing children (18). These results and those from prior studies (9) could
mean that an abnormal immune system is genetically passed on to the offspring. It is also
possible that maternal autoimmune reactions could have deleterious effects on fetal brain
development. The latter hypothesis receives support from the finding that ~12% of mothers
with children with ASD offspring have anti-fetal brain antibodies in their serum, a figure
significantly higher than in mothers of typical children (9). Animal studies support the idea
that such antibodies could be relevant for pathophysiology; when IgG from human mothers
of children with ASD is injected into rhesus macaques or mice at midgestation, some of the
offspring display abnormal behaviors that are not seen in offspring of animals injected with
IgG from mothers of typically developing children (19, 20).
Animal models of the maternal infection risk factor
The maternal infection risk factor is currently being studied in mice, rats and monkeys. The
experiments involve infecting the mother or simply activating her immune system in the
absence of pathogens.
Rodent models
The epidemiologic evidence highlighting maternal infection as a risk factor for autism and
schizophrenia has stimulated the development of several rodent models. These involve
infection of pregnant mice or rats (nasal application of influenza virus) or mimicking such
infections by activating the maternal immune system in the absence of pathogen. The latter
approach has proven particularly popular, and involves maternal injection of the synthetic
double stranded RNA, poly(I:C), to evoke an anti-viral inflammatory response, or maternal
injection of lipopolysaccharide (LPS), to evoke an anti-bacterial inflammatory response.
Although these three approaches undoubtedly yield somewhat different cascades of gene
activation, analysis of the offspring has thus far revealed considerable overlap in behavioral
abnormalities and neuropathology (4,21). Moreover, similar results have been obtained in
both the mouse and rat models of maternal immune activation (MIA). Several cardinal
symptoms of autism are observed in the offspring of immune-activated dams, including
deficits in communication (assayed by ultrasonic vocalizations; 22) and social interaction
(assayed in the 3 chamber paradigm; 23). Other behaviors in the offspring that are consistent
with autism symptoms include elevated anxiety and a prepulse inhibition deficit (4, 21).
There is also a Theory of Mind deficit in autism, in which the subject has difficulty intuiting
the thoughts of another person, which can lead to social difficulties. Approaching this type
of deficit in rodents is just beginning, using assays for empathy (24), for instance. Regarding
neuropathology, the offspring of infected mothers, or mothers given poly(I:C), also exhibit
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several abnormalities commonly found in autism including a spatially-restricted deficit in
Purkinje cells in the cerebellum (25).
Because maternal infection is a risk factor for both autism and schizophrenia, it is not
surprising that some of the features of the latter disorder have also been found in the
offspring of immune-activated mothers. These include enlarged ventricles, changes in the
serotonergic and dopaminergic pathways, as well as enhanced responses to a hallucinogen
(4, 21, 27). At least some of these symptoms can be differentially expressed as a function of
the timing of the maternal infection (28). It is also possible that the severity of MIA is a
factor in which symptoms are expressed in the offspring. Genetic background also likely
influences the outcome of maternal infection in terms of ASD versus schizophrenia. It
should also be pointed out that, in addition to the obvious phenotypic differences, there are a
number of striking similarities between schizophrenia and ASD phenotypes in humans.
These include some shared behavioral abnormalities as well as neuropathological features
(29). These overlaps in phenotypes make it difficult to firmly identify features that can be
used to distinguish ASD and schizophrenia phenotypes in animal models. The response to
hallucinogenic drugs, or even the presence of spontaneous hallucinogen-like activity in the
brain, is a potentially fruitful area that can be explored in this context. Regarding features
specific to autism, deficits in male neonate and adult communication are found in the MIA
mouse model (22), and this can be further examined by analyzing the qualitative nature of
these ultrasonic vocalizations (USVs), and as a function of the social settings in which they
occur (24). That is, experiments can evaluate the types of syllables, their grouping and order,
the consistency of usage in various social situations, how they change with development,
and whether there is indeed “mouse song” that has the characteristics of bird song.
How does activation of the maternal immune response alter fetal brain development? The
manipulation of cytokines has revealed that the elevation of the pro-inflammatory cytokine
IL-6 (which is induced by MIA) is essential for development of the abnormal behaviors and
changes in brain gene expression in the offspring (23). That is, injection of IL-6 alone is
sufficient to yield the abnormal behaviors in the offspring seen with MIA. Conversely,
blocking IL-6 during MIA prevents the development of these behaviors. Moreover,
elevation of the anti-inflammatory cytokine IL-10 also protects against MIA (30). These
results support the theory that the balance between pro-and anti-inflammatory influences is
important in fetal brain development.
Where do these cytokines act? Several groups have found that MIA induces pro-
inflammatory cytokines in the fetal brain itself. For example, IL-6 mRNA and protein are
elevated in the fetal brain following maternal poly(I:C) administration. This finding is
consistent with a feed-forward, self-reinforcing inflammatory cycle. This possibility needs
to be further tested with assays in postnatal offspring to determine if parallels to the findings
in autism brains can be found. It must also be determined if maternal IL-6 (or other signals)
is directly responsible for evoking the cytokine responses observed in the fetal brain.
Other work has highlighted the placental response to MIA as an indirect pathway towards
altering fetal brain development (31,32). Maternal injection of poly(I:C) increases IL-6
mRNA as well as maternally-derived IL-6 protein in the placenta. This activates the
endogenous immune cells in the decidua, and maternally-derived IL-6 activates the Janus
kinase (JAK)- signal transducer and activator of transcription 3 (STAT3) pathway
specifically in the spongiotrophoblast layer, which results in expression of acute phase
genes. Importantly, this parallels an IL-6-dependent disruption of the growth hormone-
insulin-like growth factor axis in the placenta. Together, these IL-6-mediated effects of MIA
represent an indirect mechanism by which MIA can alter fetal development (Fig. 1). There
is also severe placental inflammation when pregnant rats are given a high dose of LPS, and
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this reaction can be blocked by administration of an IL-1 receptor antagonist (33).
Interestingly, a greater occurrence of placental trophoblast inclusions is found in placental
tissue from births of children who go on to develop ASD compared to non-ASD controls
(34). Relevant in this context are findings that chorioamnionitis and other obstetric
complications are significantly associated with socialization and communication deficits in
autistic infants (35).
As noted above, a number of abnormalities have been found in peripheral immune cells in
autism. Thus, it is of interest that T cells in mouse MIA offspring are in a hyper-responsive
state for at least a year after birth [36]. The prolonged nature of this pathology lends further
support to the hypothesis of a feed-forward, self-reinforcing cycle that begins in during
gestation and continues through adulthood. This is also consistent with the findings of
immune-related abnormalities in the brains of adult autism cases.
Non-human primate model
Thus far, there is a single report of a non-human primate model of maternal infection using
nasal application of influenza virus in the 3rd trimester of rhesus monkey pregnancy. The
choice of 3rd trimester does not, however, fit with what is known about the windows of
vulnerability for development of schizophrenia or autism. In the offspring of the infected
monkeys, widespread reduction in gray matter volume in the cortex, and reduced white
matter volume in the parietal cortex is observed (26). The infants born to infected mothers
appear to show signs of early autonomy from the mother, yet also exhibit increased distress.
Given the striking similarities between human and non-human primate behaviors during
normal early postnatal development (unlike rodents), much could be done with this type of
model using infection, LPS or poly(I:C).
Gene-environment interactions
A variety of mental disorders have been attributed in part to genes that increase the
susceptibility to environmental risk factors. To date, however, there is very little evidence
for such gene-environment interactions. Therefore, it is of interest that mice heterozygous
for the tuberous sclerosis 2 (Tsc2) gene display a social interaction deficit only when they
are born to mothers treated with poly(I:C) (37). That is, this behavioral deficit is most severe
when the MIA environmental risk factor is combined with a genetic defect that, in humans,
also carries a high risk for ASD. In addition, there is an excess of TSC-ASD individuals
born during the peak influenza season, an association that is not seen for TSC individuals
not displaying ASD symptoms (37). Similar experiments have been done looking at the
effects of poly(I:C) MIA in lines of DISC1 mice. DISC1 (disrupted in schizophrenia 1) is a
gene associated with schizophrenia, bipolar and major depressive disorders, as well as
autism (38). In an inducible transgenic mouse line expressing a human truncated DISC1
protein in the forebrain, the combination of MIA and prenatal transgene expression results in
increased anxiety and depression-like symptoms and decreased social interaction compared
to either insult alone (39). An unexpected finding is that the combined gene-environmental
risk factors cause a decrease in ventricular enlargement compared to either alone. This
combination of insults alters the levels of several cytokines; notably IL-1β and IL-6 are
increased. Much remains to be done in this important line of experiments that combine
environmental risk factors with ASD candidate genes, both in characterizing the phenotypes
and in exploring the cellular and molecular sites of action of each factor. Results from
combining these factors should illuminate the pathways for each of them.
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Therapeutic manipulations
The findings summarized in the prior sections demonstrate that the maternal infection and
MIA models display face (similar symptoms) as well as construct (similar cause) value for
both autism and schizophrenia. These models can have predictive value as well. For
example, the manipulation of cytokines during pregnancy can prevent the development of
abnormal behaviors in the offspring in the poly(I:C) and LPS models. In addition,
pretreatment of pregnant rats with N-acetyl-cysteine, which increases calcium influx when
binding to glutamate receptors in combination with the transmitter, and also suppresses fetal
inflammatory responses to LPS, prevents many of the effects of maternal LPS
administration (4). The ability of IL-10 to block the effects of MIA is an attractive
intervention because endogenous IL-10 is essential for resistance to LPS-induced preterm
labor and fetal loss. Thus, administration of this cytokine enhances a natural protective
mechanism. However, increased IL-10 in the absence of MIA in pregnant mice can lead to
behavioral abnormalities in the adult offspring (30), a finding consistent with the fact that
normal human pregnancy involves increased inflammation. Therefore, postnatal cytokine
perturbations would potentially be a safer therapeutic approach. It is also clear that postnatal
cytokine manipulations can induce behavioral changes in the absence of MIA (40). Such
manipulations in MIA models could be a fruitful area of research.
In fact, MIA models have proven valuable for testing other types of postnatal therapies.
Whereas acute antipsychotic drug administration in adult influenza and poly(I:C) MIA
offspring can ameliorate some of the behavioral deficits (4,21), administration of such
medications in immature MIA offspring, before the onset of behavioral abnormalities and
ventricular enlargement, is effective in preventing the onset of such symptoms (41,42).
Treatment for a week during adolescence, many weeks before beginning behavioral testing,
prevents the onset of abnormalities and the ventricular enlargement. Therefore, despite the
fact that MIA has induced many changes in the brain during fetal development, postnatal
behaviors can be subsequently altered. Although the classic action of these antipsychotic
medications involves blockade of the D2 dopamine receptor in the brain, it is also worth
noting in the present context that many of them have also been shown to influence cytokine
expression in peripheral immune cells (4).
It is also important to note, in the context of potential postnatal treatments, that in mouse
models of a number of rare genetic disorders with autistic symptoms such as fragile X, Rett
syndrome and TSC, behavioral abnormalities can be at least partially reversed in adulthood.
These findings have led to several clinical trials in these disorders (43).
Concluding remarks
A variety of techniques have been used to demonstrate the presence of a sub-clinical,
inflammatory-like state in the brain, CSF and peripheral immune system in many ASD
samples. There is also evidence for abnormalities in the GI tract, although the prevalence
and the precise phenotype in that system remain to be determined. Mouse and rat models
that mimic the autism maternal infection risk factor display face, construct, and predictive
validity for ASD. Many of the symptoms in these rodent models are also similar to those
expected for a schizophrenia model, which is consistent with the fact that maternal infection
is a validated risk factor for the latter disorder as well. To aid in distinguishing ASD from
schizophrenia behavioral symptoms in this and many other animal models, it will be of great
interest to further develop assays for hallucination-like activity in the brain (27), and to
explore the qualitative features of USVs (24). The application of electrophysiological tools
to MIA models has only just begun (44, 45), and the same is true of combining MIA with
ASD candidate genes. Some of the genes near the top of the list for future testing include
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CNTNAP2 (contactin associated protein-like 2) and MET receptor kinase, the former
because of its connection with language (46), and the latter because of its roles in the
nervous, immune and GI systems (47). Another area of great promise is extending MIA to
non-human primates, where ASD-like behaviors can be assessed in much more human-like
context than in rodents. The first report on the young offspring of influenza-infected rhesus
mothers has recently appeared (26), and the development of non-human primate poly(I:C)
and LPS models should prove useful.
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Figure 1. Summary of MIA-induced effects on the placenta
Maternal injection of poly(I:C) activates the maternal immune system, elevating IL-6, which
enters the spiral arteries that descend through the decidua and spongiotrophoblast layers,
filling the maternal bloodspaces of the labyrinth. Resident immune cells in the decidua are
activated to express CD69 and further propagate the inflammatory response. IL-6 produced
by decidual cells acts on target cells in the spongiotrophoblast layer. Ligation of the IL-6Ra
with gp130 causes JAK/STAT3 activation and increases in acute phase proteins, such as
SOCS3, and down-regulation of placental growth hormone (GH) production. This leads to
reduced insulin-like growth factor binding protein 3 (IGFBP3) and IGFI. Global changes in
STAT3 activation in the spongiotrophoblast layer alter the production of placenta-specific
pro-lactin protein (PLP) and other pro-lactin proteins. These various changes in endocrine
factors very likely to lead to acute placental pathophysiology and subsequent effects on fetal
development. (Reproduced from ref. 31, with permission.)
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